The A-Z of Knowing Your Diabetes Meds!
Diabetes medications all have one goal in common: to help lower your blood glucose levels but they act in very different ways. Depending on…
This study is for people living with obesity and heart disease. Participants will start either a once weekly injection of CagriSema or placebo to their current treatment. CagriSema is a combination medication of Cagrilinitide and Semaglutide. Cagrilinitide is an investigational once-weekly injection, and Semaglutide is an FDA approved once-weekly injection (Ozempic).
The goal of the study is to assess the safety of CagriSema in people living with obesity and cardiovascular disease.
Participants will receive the study med at no charge, and will be compensated for their time and travel.
To take part in the study, participants should be:
See if you qualify
CEO and Medical Director
Director of Clinical Services
Director of Clinical Research
Clinical Research Coordinator
Clinical Research Coordinator
Navigator/Study Start-up Manager
Clinical Research Coordinator
Clinical Research Coordinator